PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design.
about
Heart Failure: Diagnosis, Management and UtilizationThe role of titin and extracellular matrix remodelling in heart failure with preserved ejection fractionChallenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"Therapeutic potential of PDE modulation in treating heart diseaseHeart failure with preserved ejection fractionShould there be sex-specific criteria for the diagnosis and treatment of heart failure?Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone.Short-term outcomes after hospital discharge in patients admitted with heart failure in Abeokuta, Nigeria: data from the Abeokuta Heart Failure Registry.Fibrosis quantification in Hypertensive Heart Disease with LVH and Non-LVH: Findings from T1 mapping and Contrast-free Cardiac Diffusion-weighted imagingPhosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease.Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary studyCardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseasesGalectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy.Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsTitin is a major human disease gene.Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in DiasLeft ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research.Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction.Pre-clinical diastolic dysfunctionImpact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.Medication management of chronic heart failure in older adults.New Insights Into Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction.Heart failure with preserved ejection fraction: current understandings and challenges.Advances in clinical cardiology.Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.Intercellular communication lessons in heart failure.High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction.Targets for Heart Failure With Preserved Ejection Fraction.CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIMEPulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprostCarotid Body-Mediated Chemoreflex Drive in The Setting of low and High Output Heart Failure.
P2860
Q26745543-77725BAE-DCA0-4BD9-A804-34E27EFADEDEQ26765101-418AE9C3-DA25-427F-B066-FD5FBE2741A2Q26785931-915C7791-1A95-484D-AD3A-A0446E3DE092Q27005761-616056C3-3081-41AE-96D4-4C206A208348Q27024008-0A686191-F2E2-4172-B1CD-B9B34309896FQ30442043-9A2CA03D-AFB9-47EB-BE66-45A16628015BQ30575578-B2F27156-E6D5-4CFD-AFC1-CBE9A595D480Q30833375-D0C54A50-AA85-46C2-9839-59C541040CFBQ30850575-8EF97B97-F114-44E6-9C91-CFBE253708C6Q33673965-32A4EC74-059A-4805-B0E4-3A7C0CB39549Q33711368-62926B5A-8789-4489-9576-4DE6CA616AA1Q33992679-1F462035-FB22-4E1D-A69E-1F0304FB3057Q34046332-26BAF6B0-B00E-4CED-8DFF-86CD2A3F919DQ34375466-458B5788-07D8-486D-9D18-C092B34D2546Q35156618-6BA7B7B0-BE94-4F04-B94C-AFACF1807B1EQ35206146-8323C5BB-96E9-45FD-B5F9-1376101D055DQ35228404-E6829148-444E-46A8-90DD-99E3703A6F8CQ35630046-6A73D06D-8D10-47B8-B37F-E1253FDE1A59Q36182164-2403A0D8-6B51-4B45-B250-90F34A68F3EBQ36460566-C7A946A2-7E36-4BCA-B489-EFD40FE3D475Q36675841-1C9FDDD6-1DA4-4641-BC26-BF4C6721117EQ36796620-96A681F3-8343-49EE-893E-0BB62BE7A2BBQ36868978-53E2D338-3D2A-49C9-A5F4-827DE7A1EBF1Q36985609-21FD6843-0C62-431D-A07D-773936B41A9BQ37328507-1E140760-95A1-4E96-8246-431DA9DB947CQ37380080-A63F9367-B591-417F-934C-15261550FD95Q37603551-587F1EE5-826E-4BEB-9B8C-FCB993E8F650Q37678145-BA73EBDE-B569-47B2-9C5D-5E3E9926B289Q38126374-87F2FEE1-89B8-455D-9574-C68DADF1E5DFQ38165710-7903719A-C67F-4EE0-B6FE-A1613B764195Q38217344-3EAF34B7-C641-4C82-85B5-D7D03E6679AAQ38235194-67DF41F5-B19E-43CB-BA50-670DA802F23DQ38380593-8AF6DE45-548C-4DED-9D54-D7054BC08835Q38591546-79799D6F-8E62-4F85-9273-65B8A0A6EC2DQ38664709-D1E4B719-F0A8-4581-AA9C-0BC9A05EEB24Q38688194-31F50A45-190A-4C90-B30E-59DC813D51D9Q38821274-6F929745-0E52-4651-BEA6-E4DB621F4AEFQ39227748-A5F72ADF-43F9-42F8-B583-2A8B5762AA20Q39856692-242AC2D3-DBEC-46AD-9D5C-913B8FFBC535Q41387881-850F2542-73A7-4075-831F-4C5AA306BDE5
P2860
PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
PhosphdiesteRasE-5 Inhibition ...... ) trial: rationale and design.
@en
type
label
PhosphdiesteRasE-5 Inhibition ...... ) trial: rationale and design.
@en
prefLabel
PhosphdiesteRasE-5 Inhibition ...... ) trial: rationale and design.
@en
P2093
P2860
P1476
PhosphdiesteRasE-5 Inhibition ...... ) trial: rationale and design.
@en
P2093
Anita Deswal
Barry A Borlaug
Greg D Lewis
Heart Failure Clinical Research Network
Kerry L Lee
Marc J Semigran
Margaret M Redfield
Martin M Lewinter
Selma F Mohammed
P2860
P304
P356
10.1161/CIRCHEARTFAILURE.112.969071
P577
2012-09-01T00:00:00Z